Undisclosed MYC c-mod / Dewpoint Therap - LARVOL DELTA

Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate (GlobeNewswire) - "The MYC DC is a first-in-class small molecule designed to disrupt MYC-driven oncogenic transcription by modulating the aberrant biomolecular condensates that organize transcriptional control in cancer cells....The MYC DC was selected based on a comprehensive preclinical data package demonstrating potency and specificity in MYC-dependent cellular systems, favorable in vivo pharmacology, including tumor regressions in MYC-dependent models....Dewpoint is prepared to advance the MYC DC through IND-enabling studies while continuing to deepen its understanding of MYC condensate biology across cancer models."

Pipeline update • Preclinical • Oncology

Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025 (GlobeNewswire) - "Oral condensate modulators (c-mods) demonstrate efficient and selective killing of cancer cells in multiple pre-clinical models of MYC-driven cancers."

Preclinical • Solid Tumor

Dewpoint Therapeutics…announced the closing of its Series D financing to advance DPTX3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end 2025 and deliver early clinical proof-of-concept by the end of 2026 (GlobeNewswire) - "It will also accelerate development of Dewpoint’s first-in-class c-mod targeting MYC...while strengthening ongoing collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma. The financing provides operational runway into early 2027."

Financing • New trial • Gastric Cancer • Ovarian Cancer

Dewpoint Therapeutics announces upcoming presentations at AACR 2025 (GlobeNewswire) - "Dewpoint will present two posters at AACR; Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer; C-mods modulate the oncogenic function of historically undruggable targets MYC and beta catenin."

Preclinical • Oncology • Ovarian Cancer